Last reviewed · How we verify
CD0271
CD0271 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.
CD0271 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | CD0271 |
|---|---|
| Also known as | Adapalene 0.1% Gel |
| Sponsor | Galderma R&D |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels, which suppresses the production of pro-inflammatory cytokines and chemokines from immune cells. This mechanism is intended to reduce inflammation in dermatological conditions. CD0271 is being developed by Galderma for inflammatory skin diseases.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Efficacy and Safety of CD5024 1% in Acne Vulgaris (PHASE2)
- A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients (PHASE1)
- Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris (PHASE3)
- Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD0271 CI brief — competitive landscape report
- CD0271 updates RSS · CI watch RSS
- Galderma R&D portfolio CI